Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaun M Cote

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Biochemistry|October 24, 2012
Binding efficiency of protein-protein complexesEric S Day, Shaun M Cote, Adrian Whitty
SLAS Discovery : Advancing Life Sciences R & D|July 27, 2019
A Sensitive and Selective Immunoassay for the Quantitation of Serum Latent Myostatin after In Vivo Administration of SRK-015, a Selective Inhibitor of Myostatin ActivationShaun M Cote, Justin Jackson, Michelle Pirruccello-Straub, et al.
International Journal of Toxicology|July 13, 2021
Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying DiseaseBrian T Welsh, Shaun M Cote, Deborah Meshulam, et al.
Biochemistry|November 26, 2013
Mutation of nonessential cysteines shows that the NF-κB essential modulator forms a constitutive noncovalent dimer that binds IκB kinase-β with high affinityShaun M Cote, Thomas D Gilmore, Robert Shaffer, et al.
Advances in Therapy|May 8, 2021
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular AtrophyDoreen Barrett, Sanela Bilic, Yung Chyung, et al.
Journal of the American Chemical Society|March 20, 2013
Comprehensive experimental and computational analysis of binding energy hot spots at the NF-κB essential modulator/IKKβ protein-protein interfaceMary S Golden, Shaun M Cote, Marianna Sayeg, et al.
Human Molecular Genetics|November 28, 2018
Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapyKimberly K Long, Karen M O'Shea, Ramzi J Khairallah, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Biochemistry|October 24, 2012
Binding efficiency of protein-protein complexesEric S Day, Shaun M Cote, Adrian Whitty
SLAS Discovery : Advancing Life Sciences R & D|July 27, 2019
A Sensitive and Selective Immunoassay for the Quantitation of Serum Latent Myostatin after In Vivo Administration of SRK-015, a Selective Inhibitor of Myostatin ActivationShaun M Cote, Justin Jackson, Michelle Pirruccello-Straub, et al.
International Journal of Toxicology|July 13, 2021
Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying DiseaseBrian T Welsh, Shaun M Cote, Deborah Meshulam, et al.
Biochemistry|November 26, 2013
Mutation of nonessential cysteines shows that the NF-κB essential modulator forms a constitutive noncovalent dimer that binds IκB kinase-β with high affinityShaun M Cote, Thomas D Gilmore, Robert Shaffer, et al.
Advances in Therapy|May 8, 2021
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular AtrophyDoreen Barrett, Sanela Bilic, Yung Chyung, et al.
Journal of the American Chemical Society|March 20, 2013
Comprehensive experimental and computational analysis of binding energy hot spots at the NF-κB essential modulator/IKKβ protein-protein interfaceMary S Golden, Shaun M Cote, Marianna Sayeg, et al.
Human Molecular Genetics|November 28, 2018
Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapyKimberly K Long, Karen M O'Shea, Ramzi J Khairallah, et al.
Pageof 1